---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032468"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:06:14.196640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)

## Summary
- Revenue surged 234% to $509,589 driven by licensing milestones.
- Net loss improved to $4.90M from $7.79M; EPS improved 77% to $(0.42).
- Operating expenses reduced 21% to $5.21M, R&D down 83%, SG&A down 58%.
- Stock-based compensation increased to $2.77M from $0.19M to preserve cash.
- Remaining milestone potential of up to $18.3M under existing licensing deals.

## SEC filing metadata
- accession: 0001213900-25-032468
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/0001213900-25-032468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/ea0238544-8ka1_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032468
- JSON: https://secwatch.observer/filing/0001213900-25-032468.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.